1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Bajaj Healthcare Ltd

Bajaj Healthcare Ltd

BAJAJHCARE.BO
Bajaj Healthcare LtdIN flagBombay Stock Exchange
337.45
INR
+6.10
- -
11.35BMarket Cap
Bajaj Healthcare Ltd
BAJAJHCARE.BO
(Bombay Stock Exchange)

Recent

price

337.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
43.43
51.27
61.88
74.01
78.51
82.53
74.28
104.02
117.13
147.74
237.62
246.35
234
171.35
182.58
193.01
181.12
Revenue per Share
1.54
0.24
-0.38
0.71
2.72
3.04
2.84
5.5
5.91
9.14
30.11
25.87
15.59
-30.36
13.29
4.98
14.32
Basic EPS, GAAP
-4.5
-3.09
-0.63
2.44
3.44
-2.05
4.36
1.85
3.68
-0.77
-25.45
-28.49
-41.95
22.47
3.39
4.65
- -
Free Cash Flow per Basic Share
- -
0.1
- -
- -
- -
- -
- -
- -
0.25
- -
0.88
0.5
1.5
1
0.93
1
- -
Dividend per Share
7.58
7.82
7.44
8.15
10.87
15.57
18.44
23.94
52.98
64.55
93.79
119.16
133.24
101.88
107.65
5.32
- -
Book Value per Share
10.23
10.47
10.08
10.8
13.52
32.83
35.95
41.17
55.39
64.47
93.63
119.02
132.73
100.2
156.39
168.05
- -
Tangible Book Value per Share
28
28
28
28
28
27
28
28
28
28
28
28
28
28
30
32
31
Basic Weighted Avg Shares
1,199
1,415
1,708
2,042
2,167
2,228
2,046
2,871
3,233
4,078
6,558
6,799
6,458
4,729
5,426
6,110
5,592
Sales/Revenue/Turnover
7.52
4.02
2.75
5.09
9.16
9.84
9.59
-9.07
10.65
11.44
18.48
15.31
14.6
10.3
10.05
12.65
9.94
Operating Margin (%)
47
56
81
89
89
93
113
111
114
121
161
176
274
314
279
275
268
Depreciation Expense
45
7
-11
20
75
82
78
152
163
252
831
714
430
-838
395
158
442
Net Income, GAAP
23.69
38.15
- -
40.07
37.46
39.25
- -
33.05
32.52
30.02
30.05
20.4
18.74
- -
6.69
26.32
6.5
Effective Tax Rate (%)
3.73
0.46
-0.62
0.97
3.47
3.68
3.83
5.29
5.05
6.19
12.67
10.5
6.66
-17.72
7.28
2.58
7.9
Profit Margin (%)
-80
-108
-128
-128
-52
-101
-15
85
130
308
758
762
668
386
2,639
3,065
- -
Working Capital
120
174
171
145
222
314
268
215
174
236
797
663
944
391
649
506
- -
LT Debt
297
304
293
313
388
886
990
1,136
1,529
1,779
2,584
3,285
3,677
2,784
4,662
5,330
- -
Total Equity
- -
4.03
- -
6.05
11.5
9.42
- -
-9.54
10.84
13.16
24.02
15.92
10.92
- -
7.86
7.74
- -
Return on Invested Capital (%)
- -
4.64
- -
6.74
12.8
11.09
- -
14.57
11.12
12.05
25.1
15.63
8.23
- -
11.33
7.95
18.13
Return on Capital (%)
- -
3.06
-5.02
9.17
28.63
22.76
16.86
25.99
15.37
15.56
38.04
24.29
12.35
-25.83
13.14
9.36
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
1,583
- -
LT Borrowings
- -
647
- -
LT Finance Leases
- -
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
32
- -
Market Capitalization
16,817
20,049
15,587

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
5,609
- -
Cash, Cash Equivalents & STI
- -
379
- -
Accounts Receivable, Net
- -
2,517
- -
Inventories
- -
1,619
- -
Total Current Liabilities
- -
2,970
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,583
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.92%
19.31%
14.34%
Free Cash Flow
269.35%
-26.39%
46.12%
Net Income, GAAP
-17.49%
-111.16%
-60.08%
Sales/Revenue/Turnover
13.1%
-0.15%
12.61%
Total Cash Common Dividend
- -
- -
14.44%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,297
1,012
1,086
1,339
4,729
2025
1,322
1,331
1,228
1,545
5,426
2026
1,488
1,612
1,531
- -
6,110

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-17.47
-1.25
-0.8
- -
-30.36
2025
2.59
3.36
3.65
3.54
13.29
2026
3.74
4.96
-7.16
- -
4.98

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
0.93
2026
- -
- -
- -
- -
1
Similar Companies
Synmosa Biopharma Corporation (4114.TWO)
Imagenetix, Inc. (IAGX)
PT Industri Jamu dan Farmasi Sido Muncul Tbk (SIDO.JK)
Zydus Lifesciences Limited (CADILAHC.NS)
Galderma Group AG (GALD.SW)
Zydus Lifesciences Limited (ZYDUSLIFE.NS)
Business
Bajaj Healthcare Limited Bajaj Healthcare Limited (BAJAJHCARE.BO) manufactures active pharmaceutical ingredients, intermediates, nutritional supplements including amino acids, and finished dosage formulations such as tablets, capsules, and powders for the pharmaceutical, nutraceutical, and food industries in India and internationally; its active pharmaceutical ingredients span therapeutic categories including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, iron-chelating agents, anticonvulsants, non-steroidal anti-inflammatory drugs, antihypertensives, anthelmintics, anti-asthmatics, antioxidants, urinary tract infection treatments, antihistamines, antimalarials, vitamins, disinfectants, lipotropic agents, nootropics, cardiovascular agents, anti-anemics, bronchodilators, and minerals, with specific products such as fosfomycin salts, ascorbyl palmitate, carbamazepine, oxcarbazepine, chlorhexidine derivatives, citicoline sodium, and deferasirox. Founded in 1993 and headquartered in Thane, India, the company operates manufacturing facilities in Tarapur and Panoli in Maharashtra and Gujarat, and Vadodara, serving over 550 clients and exporting to more than 62 countries across Europe, the US, Africa, and Australia. In April 2025, Bajaj Healthcare Limited acquired WHO-GMP certified Genrx Pharmaceuticals Private Limited for Rs 10.85 crore in cash as a going concern to expand its formulations manufacturing capabilities and leverage synergies for growth, with completion expected within 36 months subject to regulatory approvals.